REGEN-COV is a monoclonal antibody treatment for coronavirus disease 2019 (COVID-19). Casirivimab and imdevimab are the investigational medicines used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Casirivimab and imdevimab are investigational because they are still being studied. There is limited information known about the safety and effectiveness of using casirivimab and imdevimab to treat people with COVID-19. The FDA has authorized the emergency use of casirivimab and imdevimab for the treatment of COVID-19 under an Emergency Use Authorization (EUA).
- Hospitalized for COVID-19
- Age <12
- Weight <40kg
- Requiring oxygen for COVID-19
(or increased oxygen requirements due to COVID in a patient who already received oxygen therapy)
Note: Please speak with your healthcare provider for more information if you think this therapy might be right for you.
How do I make a referral or transition my treatment to Infusion Associates?
3. One of our intake specialists will contact you to confirm receipt of your referral.
4. We will then verify benefits, obtain any required prior authorizations, and contact you to schedule an appointment.